Nanosonics has not disclosed specific distributors for Coris yet. However, their strategy seems to involve a phased rollout, starting with direct engagement with hospitals in the U.S. market. This approach mirrors their successful distribution model for the Trophon line, which has a strong presence in the U.S. healthcare sector. GE does not involve endoscopes in its business engagements. The GS analyst did not know this and was quite humiliated in front of his fellow analysts. The business community in the USA is currently in a quandary and their operations receive unexpected calls from the Trump admin re such things as DEI and so called woke business practices. So I expect NAN to leverage its own network of Sales in the Luminary hospitals and Private Physicians.
NAN Price at posting:
$4.64 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)